Meropenem overdosage: Difference between revisions
Created page with "__NOTOC__ {{Meropenem}} {{CMG}} ==Overdosage== In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, ..." |
No edit summary |
||
| Line 11: | Line 11: | ||
Limited post-marketing experience indicates that if adverse events occur following overdosage, they are consistent with the adverse event profile described in the Adverse Reactions section and are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered. In individuals with normal renal function, rapid renal elimination takes place. | Limited post-marketing experience indicates that if adverse events occur following overdosage, they are consistent with the adverse event profile described in the Adverse Reactions section and are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered. In individuals with normal renal function, rapid renal elimination takes place. | ||
Meropenem and its metabolite are readily dialyzable and effectively removed by [[hemodialysis]]; however, no information is available on the use of [[hemodialysis]] to treat overdosage. | Meropenem and its metabolite are readily dialyzable and effectively removed by [[hemodialysis]]; however, no information is available on the use of [[hemodialysis]] to treat overdosage.<ref>{{Cite web | last = | first = |title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf | publisher = |date = | accessdate = }}</ref> | ||
==References== | |||
{{Reflist}} | |||
{{FDA}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 22:18, 20 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overdosage
In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.
Intentional overdosing of Meropenem is unlikely, although accidental overdosing might occur if large doses are given to patients with reduced renal function. The largest dose of meropenem administered in clinical trials has been 2 g given intravenously every 8 hours. At this dosage, no adverse pharmacological effects or increased safety risks have been observed.
Limited post-marketing experience indicates that if adverse events occur following overdosage, they are consistent with the adverse event profile described in the Adverse Reactions section and are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered. In individuals with normal renal function, rapid renal elimination takes place.
Meropenem and its metabolite are readily dialyzable and effectively removed by hemodialysis; however, no information is available on the use of hemodialysis to treat overdosage.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.